文献速递肿瘤 PET/CT

含RGD基序的αvβ6整合素结合肽SFLAP3与SFITGv6用于头颈部鳞状细胞癌诊断应用的比较

Comparison of the RGD Motif-Containing αvβ6 Integrin-Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC.
PubMed 文献 · J Nucl Med · 2018-04-19

本研究合成5种含RGD基序的αvβ6整合素结合肽,与SFITGv6比较亲和力与特异性。SFLAP3和SFITGv6对多种头颈部鳞状细胞癌细胞系显示显著结合(>20%)及快速内化(分别达60%和70%),SFLAP3对αvβ6整合素亲和力改善(平均半数抑制浓度3.5 nM;解离常数7.4)。在小鼠模型中68Ga或177Lu标记的DOTA-SFLAP3注射后30-60分钟肿瘤特异性摄取增加,一例患者PET/CT显示原发灶SUVmax 5.1、淋巴结转移灶SUVmax 4.1。

要点

  • SFLAP3和SFITGv6对HNO97、HNO399和HNO223细胞系结合>20%,内化分别达60%和70%。
  • SFLAP3对αvβ6整合素平均半数抑制浓度3.5 nM,解离常数7.4。
  • 一例HNSCC患者PET/CT示原发灶SUVmax 5.1、淋巴结转移灶SUVmax 4.1。

核心结论

  • SFLAP3是用于αvβ6整合素表达肿瘤预后评估、诊断显像及可能靶向治疗的有前景示踪剂。

研究设计与样本

  • 合成5种基于向日葵胰蛋白酶抑制剂1(SFTI1)的含RGD基序八肽(SFFN1、SFTNC、SFVTN、SFLAP1、SFLAP3),与SFITGv6比较,体外评估稳定性、亲和力与特异性,并行小鼠HNSCC模型小动物PET显像与生物分布实验,及一例HNSCC患者68Ga-DOTA-SFLAP3 PET/CT诊断显像。

主要发现

  • SFLAP3(GRGDLGRL)和SFITGv6(FRGDLMQL)对HNO97、HNO399和HNO223细胞系结合>20%,内化分别达60%和70%。
  • SFLAP1结合4.1%-12.1%,SFFN1、SFTNC、SFVTN结合<1%,被排除进一步分析。
  • SFLAP3对αvβ6整合素平均半数抑制浓度为3.5 nM,解离常数为7.4。
  • HNSCC异种移植小鼠注射68Ga或177Lu标记DOTA-SFLAP3后30-60分钟肿瘤特异性累积增加。
  • 一例HNSCC患者PET/CT示原发肿瘤病灶SUVmax 5.1,相应淋巴结转移灶SUVmax 4.1。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

αvβ6 integrin is overexpressed by several carcinomas and thus considered a target for diagnostic imaging and anticancer therapies. Recently, we presented the αvβ6 integrin-binding peptide SFITGv6 as a novel potential tracer for imaging and targeted therapy of αvβ6 integrin-positive carcinomas. Here, we analyzed the affinity and specificity of 5 native αvβ6 integrin-specific binders in comparison to SFITGv6. Methods: Sunflower trypsin inhibitor 1 (SFTI1)-based peptides containing arginine-glycine-aspartic acid (RGD) motif-spanning octamers of fibronectin (SFFN1), tenascin C (SFTNC), vitronectin (SFVTN), and latency-associated peptides (LAP) 1 (SFLAP1) and 3 (SFLAP3) were synthesized, and their binding potential to αvβ6 integrin-expressing head and neck squamous cell carcinoma (HNSCC) cell lines was evaluated. Subsequently, stability, affinity, and specificity were assessed in vitro using radio-high-pressure liquid chromatography, surface plasmon resonance assay, and binding experiments including competition, kinetics, internalization, and efflux. αvβ6 integrin binding specificity was further evaluated by peptide histochemistry. Finally, in vivo binding properties were assessed using small-animal PET imaging and biodistribution experiments in HNSCC-bearing mice, and 68Ga-DOTA-SFLAP3 was applied for diagnostic PET/CT of an HNSCC patient. Results: When the newly designed peptides were compared, significant binding (>20%) to several HNSCC cell lines (HNO97, HNO399, and HNO223) and a fast internalization of up to 60% and 70% were observed for SFLAP3 (GRGDLGRL) and SFITGv6 (FRGDLMQL). In contrast, the other peptides displayed binding that was moderate (SFLAP1, 4.1%-12.1%) to marginal (SFFN1, SFTNC, and SFVTN, <1%) and were therefore excluded from further analysis. Notably, SFLAP3 exhibited improved affinity for αvβ6 integrin (mean half-maximal inhibitory concentration, 3.5 nM; dissociation constant, 7.4). Moreover, small-animal PET imaging and biodistribution studies of HNSCC xenograft mice revealed an increased tumor-specific accumulation 30-60 min after injection of 68Ga-labeled or 177Lu-labeled DOTA-SFLAP3. Peptide staining further demonstrated binding specificity for SFLAP3 to HNSCC tumor cells. Finally, PET/CT scanning of an HNSCC patient showed specific SFLAP3 accumulation in the primary tumor lesion (SUVmax, 5.1) and in corresponding lymph node metastases (SUVmax, 4.1). Conclusion: SFLAP3 represents a promising tracer for prognostic assessment, diagnostic imaging, and possibly targeted therapy of αvβ6 integrin-expressing tumors.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Roesch S, Lindner T, Sauter M, et al. Comparison of the RGD Motif-Containing αvβ6 Integrin-Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC. J Nucl Med. 2018. PMID: 29674419. doi:10.2967/jnumed.118.210013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。